Intangible Assets

ARGX’s FcRn platform is protected by a dense patent estate and biologics know-how, which raises replication difficulty versus peers such as UCB and Roche even though the underlying target class is now validated.

Vyvgart’s first-mover regulatory and clinical evidence in generalized myasthenia gravis and CIDP supports durable physician familiarity and label credibility, which is harder for later entrants to displace than for broader immunology peers.

The company’s focus on complex antibody engineering and manufacturing process expertise creates tacit know-how that is less transferable than small-molecule or follow-on biologic capabilities at many peers.

Intangible assets are strong but not absolute because the FcRn mechanism has attracted multiple competitors, so the moat is durable yet still contestable versus larger immunology franchises.

Switching Costs

Once patients are stabilized on Vyvgart, physicians face clinical inertia and monitoring risk when switching therapies, which supports retention versus peers with less differentiated efficacy or tolerability.

Specialty-channel access, prior authorization workflows, and payer re-approval create administrative friction that makes switching costly in practice, especially compared with more commoditized autoimmune therapies.

In rare disease settings, treatment continuity matters more than in broad primary-care markets, so established response data can keep patients on therapy longer than in peer biologic categories with many interchangeable options.

Switching costs are meaningful but not dominant because alternative FcRn or immunology therapies can still be substituted if payers prefer lower-cost options or if competing labels broaden.

Network Effects

ARGX does not benefit from a true user-to-user network effect because prescribing decisions are made by clinicians and payers rather than by a growing installed base of end users.

Clinical evidence can reinforce adoption over time, but that is a reputation effect rather than a self-reinforcing network comparable to platform businesses or data networks.

Peer comparison is unfavorable because larger pharma companies can leverage broader commercial footprints and cross-portfolio relationships, while ARGX’s product adoption remains indication-specific.

Any ecosystem benefits are indirect and limited to specialist familiarity, so they do not create a durable network moat.

Cost Advantage

ARGX’s focused R&D model can allocate capital efficiently to a small number of high-value programs, which can produce better productivity than diversified peers with broader but less concentrated pipelines.

The company’s biologics expertise and platform reuse can lower incremental development costs relative to peers starting from scratch, but this advantage is not large enough to guarantee structurally lower costs.

Favorable cash conversion metrics are not a moat by themselves, but they are consistent with a business that can scale commercialization without the heavy fixed-cost burden seen at larger diversified peers.

Cost advantage is moderate because large peers such as Roche, AstraZeneca, or UCB can spread fixed costs across bigger revenue bases and often match or exceed ARGX’s manufacturing and commercial scale.

Efficient Scale

ARGX operates in rare and specialty autoimmune indications where the addressable patient pool is limited, so a focused leader can capture enough share to support attractive economics without needing mass-market scale.

The economics of specialist education, payer access, and post-launch evidence generation favor a small number of credible players, which makes the market less hospitable to many entrants than broad immunology markets.

Vyvgart’s commercial footprint can be efficient because each additional indication can leverage the same specialist prescriber base and infrastructure, improving scale economics versus peers with fragmented portfolios.

Efficient scale is strong but not absolute because large pharma peers can still enter with superior commercial reach and capital, so the barrier is meaningful rather than structurally exclusive.

Overall Score

ARGX has a strong but not dominant moat: its best defenses come from patent-protected FcRn innovation, clinical credibility, and efficient scale in rare autoimmune markets, while switching costs are real and network effects are weak, leaving the franchise durable versus peers but still contestable by larger immunology competitors.